Business Description
Immunome Inc
NAICS : 541714
SIC : 2833
ISIN : US45257U1088
Share Class Description:
IMNM: Ordinary SharesTotal Employee Number:
177Description
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 157.74 | |||||
Equity-to-Asset | 0.95 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.02 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 49.72 | |||||
Beneish M-Score | -3.6 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 5.4 | |||||
3-Year EPS without NRI Growth Rate | 7.7 | |||||
3-Year FCF Growth Rate | 0.3 | |||||
3-Year Book Growth Rate | 59.8 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 20.39 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 269.06 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 94.27 | |||||
9-Day RSI | 83.07 | |||||
14-Day RSI | 72.02 | |||||
3-1 Month Momentum % | -11.45 | |||||
6-1 Month Momentum % | -7.11 | |||||
12-1 Month Momentum % | 124.1 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 21.68 | |||||
Quick Ratio | 21.68 | |||||
Cash Ratio | 21.26 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -110.5 | |||||
Shareholder Yield % | -18.95 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -5947.9 | |||||
Net Margin % | -5593.85 | |||||
EBITDA Margin % | -5873.62 | |||||
FCF Margin % | -5343.41 | |||||
OCF Margin % | -4894.2 | |||||
ROE % | -54.42 | |||||
ROA % | -50.1 | |||||
ROIC % | -790.16 | |||||
3-Year ROIIC % | -550.98 | |||||
ROC (Joel Greenblatt) % | -1462.91 | |||||
ROCE % | -57.3 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 518.45 | |||||
PB Ratio | 4.59 | |||||
Price-to-Tangible-Book | 4.59 | |||||
EV-to-EBIT | -8.89 | |||||
EV-to-Forward-EBIT | -8.39 | |||||
EV-to-EBITDA | -9 | |||||
EV-to-Revenue | 528.52 | |||||
EV-to-Forward-Revenue | 349.14 | |||||
EV-to-FCF | -9.89 | |||||
Price-to-GF-Value | 11.87 | |||||
| Price-to-Net-Current-Asset-Value | 4.79 | |||||
| Price-to-Net-Cash | 4.9 | |||||
Earnings Yield (Greenblatt) % | -11.25 | |||||
FCF Yield % | -7.94 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:IMNM
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Immunome Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 4.015 | ||
| EPS (TTM) ($) | -2.38 | ||
| Beta | 1.2529 | ||
| 3-Year Sharpe Ratio | 0.74 | ||
| 3-Year Sortino Ratio | 1.37 | ||
| Volatility % | 50.17 | ||
| 14-Day RSI | 72.02 | ||
| 14-Day ATR ($) | 1.121872 | ||
| 20-Day SMA ($) | 19.418 | ||
| 12-1 Month Momentum % | 124.1 | ||
| 52-Week Range ($) | 7.96 - 27.65 | ||
| Shares Outstanding (Mil) | 113.25 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Immunome Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Immunome Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-06 | In 123 days | ||
| Second quarter earnings results for 2026 | 2026-08-06 | In 31 days | ||
| General meeting for 2026 | 2026-06-09 12:00 | 18.61 (-1.69%) | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-09 10:40 | 18.61 (-1.69%) | ||
| First quarter earnings results for 2026 | 2026-05-12 | 23.00 (+2.18%) | ||
| Leerink Partners Global Healthcare Conference | 2026-03-10 15:00 | 21.33 (+3.29%) | ||
| TD Cowen 46th Annual Health Care Conference | 2026-03-03 09:50 | 22.21 (+4.71%) | ||
| Annual report for 2025 | 2026-03-03 | 22.21 (+4.71%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-03 | 22.21 (+4.71%) | ||
| Guidance call for 2026 | 2026-02-11 09:00 | 24.93 (+1.01%) |
Show
Entries
Immunome Inc Frequently Asked Questions
What is Immunome Inc(IMNM)'s stock price today?
The current price of IMNM is $23.85. The 52 week high of IMNM is $27.65 and 52 week low is $7.96.
When is next earnings date of Immunome Inc(IMNM)?
The next earnings date of Immunome Inc(IMNM) is 2026-08-06 Est..
Does Immunome Inc(IMNM) pay dividends? If so, how much?
Immunome Inc(IMNM) does not pay dividend.
Guru Commentaries on NAS:IMNM
No articles.
Press Release
Articles on Immunome Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers